Japan Life Science Seminar – Doing Business with JAPAN in the Medical Devices Sector, Hall C2
The Japan External Trade Organization, the Embassy of Japan, the Israeli Ministry of Economy & Industry and the Israel Export & International Cooperation Institute cordially invites you to the ‘Doing Business with JAPAN’ Seminar.
Organized by: JETRO (Japan External Trade Organization) Tel-Aviv and the Israeli Ministry of Economy and Industry, the Israel Export & International Cooperation Institute
Co-Hosted by: the Embassy of JAPAN in Israel
CDI, Overview on the Japanese medical device market (presenter name to be updated)
Life Science Institute, Mr. Hideaki Matsumoto, Business strategy and new trends
Mitsubishi Tanabe Pharma, Mr. Toshiro Sakaki, Business strategy and new trends
Corundum Open Innovation, David Ben-Ami, A Japanese Life Science VC in Israel
Itamar Medical, Ira Prigat, Vice President, Sales and Marketing Japan and China – Success Counts Beyond the Market Entry Stage
STI-Laser, Tovy Sivan, CEO, Drivers for success in Japan
JETRO, Medical Device and Healthcare sector in JAPAN
Networking & Refreshments
Accessing the NHS in the UK (National Health Services), Hall C2
Focused seminar for the Medical Device & HealthCare IT Industry
Mr. Chris Slater, Associate Director, Commercial I Procurement Leeds Teaching Hospitals NHS Trust, UK
Dr. Neville Young, Head of Commercial Development, Yorkshire & Humber Academic Health Science Network, UK
There are many difference ways of suppling products to the NHS. NHS organizations in England try to make most effective use of their resources by getting the best possible value for money purchasing and spending over 25£ billion every year on variety of goods and services. Effective management of this resources is vital, the Department of Health Strategy build a modern, effective and efficient procurement capability looking for high quality innovation that demonstrates BOTH Clinical Utility and Cost Effectiveness.
Do you really understand the UK healthcare pathway you wish to operate in and if not how do you map this pathway so that you can identify where in it your innovation will have the best effect (clinically and economically)? What does clinical utility and cost effectiveness really look like in the NHS? Will your current clinical evidence stack up in the UK?
Do you understand the incentives in the system that might drive adoption? Who will administer it and where the benefit falls?
In this seminar will address: